Relmada Therapeutics Investor Relations Material
Latest events
Q4 2023
Relmada Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Relmada Therapeutics Inc
Access all reports
Relmada Therapeutics Inc. is a clinical-stage biotechnology company focusing on developing innovative treatments for central nervous system (CNS) diseases, with a particular emphasis on major depressive disorder. The company's flagship product, esmethadone (d-methadone, dextromethadone, REL-1017), is a novel N-methyl-D-aspartate (NMDA) receptor antagonist currently inclinical trials, aimed at serving as an adjunctive or monotherapy treatment for MDD in adults. The company is headquartered Coral Gables, Florida. Its shares are listed on the Nasdaq.
Latest articles
Four Decades of IPOs: An Overview
An overview of the stock and IPO market from the 80's until today, highlighting important events and trends.
24 Apr 2024
Larry Page: The Mastermind Behind Google
Explore the journey of Larry Page from a tech-savvy youth to co-founding Google and leading Alphabet.
24 Apr 2024
Mark Leonard: The Mysterious Brain Behind Constellation Software
Information about Mark Leonard is scarce, and one of the only ways to “get to know” him is through his shareholder letters. Join us in an attempt to do so.
24 Apr 2024
Ticker symbol
Country
🇺🇸 United States